Panbela Therapeutics, Inc. Common Stock

PBLA

...

PBLA: Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Show PBLA Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of PBLA by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

No Whale Activity for this ticker

Institutional Holdings Dashboard

Insider Trading

Quarterly net insider trading by PBLA's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

Patent Title: Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Feb. 28, 2023
Patent Title: Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Aug. 24, 2021

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on PBLA's company Twitter account

WallStreetBets

Number of mentions of PBLA in WallStreetBets Daily Discussion

PBLA News

Recent insights relating to PBLA

CNBC Recommendations

Recent picks made for PBLA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PBLA

Corporate Flights

Flights by private jets registered to PBLA